Q1 2020

Filed May 13, 2020 · 10-Q · 43 days after period end · 0001213900-20-011964

Q1 2020 · 10-Q

Revenue—

Net Income

-$540.50K

N/M vs Q1 2019

EPS Diluted

-$0.01

— vs Q1 2019

Operating Income-$266,043N/M

Operating Cash Flow-$156,789N/M

Same quarter

Metric	Q1 2020	Q1 2019	Q1 2018	Q1 2017
Revenue	—	—	$13.32K	$7.44K
Net Income	-$540.50K	-$191.41K	-$29.61K	-$64.59K
EPS Diluted	-$0.01	$0.00	$0.00	-$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR